Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The cyclin-dependent kinase (CDK) inhibitor p27 Kip1 is a tumor suppressor frequently downregulated in cancers.
• HER2, a receptor tyrosine kinase oncogene, promotes cancer cell growth and transformation by enhancing p27 Kip1 degradation.
• p27 Kip1 degradation is mediated by ubiquitination, influenced by JAB1 binding and Thr187 phosphorylation.

Purpose of the Study:

• To develop novel anticancer agents by modifying p27 Kip1 to resist HER2-mediated degradation.
• To evaluate the efficacy of modified p27 Kip1 proteins in inhibiting HER2-overexpressing cancer cells and tumors.

Main Methods:

• Generation of modified p27 Kip1 proteins with mutations at Thr187 (p27 T187A) or deletion of the JAB1 binding domain (p27 DeltaJAB).
• Utilized a tetracycline-regulated gene expression system to control the delivery of modified p27 Kip1 genes.
• Assessed the impact of modified p27 Kip1 on HER2-activated cell growth, CDK2 activity, proliferation, and transformation in vitro.
• Evaluated tumor volume reduction in a HER2-overexpressing tumor model in vivo.

Main Results:

• Engineered p27 T187A and p27 T187A DeltaJAB proteins effectively inhibited HER2-driven cell growth, CDK2 activity, proliferation, and transformation.
• The modified protein p27 T187ADeltaJAB significantly reduced tumor volume in a HER2-overexpressing tumor model.
• These findings highlight the therapeutic potential of stabilized p27 Kip1 variants.

Conclusions:

• Modified p27 Kip1 proteins, resistant to degradation, can serve as effective anticancer agents against HER2-overexpressing cancers.
• Targeting p27 Kip1 stability presents a promising therapeutic strategy for HER2-driven malignancies.
• This study demonstrates the clinical applicability of engineered p27 Kip1 proteins in cancer therapy.